---
title: "BY-COVID"
summary: "BY-COVID aims to make data about SARS-CoV-2 and other viruses easier to access, aggregate, and analyse"
status: "completed"
category: "european"
funder:
    name: "European Commission"
    link: https://ror.org/00k4n6c32
project_number:
    grant_agreement_id: 101046203
    link: https://doi.org/10.3030/101046203
period: 2021-10 2024-09
external_link: https://by-covid.org/
keywords: ["pathogen", "covid", "brokering"]
draft: false
---

BY-COVID is a project funded under the European Unionâ€™s Horizon Europe Research and Innovation Programme. 
It aims to make data about SARS-CoV-2 and other viruses easier to access, aggregate, and analyse. 
This will enable scientists to respond faster to new strains of SARS-CoV-2 or to new viruses. 
It will also help policy-makers assess the impact of the disease and take the most appropriate measures to protect people against new viral diseases.
ELIXIR Norway contributes to work package 1 on support for virological analyses in emerging disease outbreaks (UiT). The Centre for Information Technology (USIT) at the University of Oslo contributes to work package 5 on facilitating secondary use of COVID-19 vaccine trial data and biosamples to test existing vaccines against emerging variants, using TSD as the data repository to access trial data.
